News

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more ...
Ophthalmology Times1d
Ocugen signs term sheet for korean licensing of OCU400 gene therapy
OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...
BioSpace23h
uniQure’s Regulatory Progress Sparks Optimism for ‘Desperate’ Huntington’s Space
Analysts reacted positively to the news that uniQure is in alignment with the FDA on an accelerated approval pathway and on ...
Business Wire1mon
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with ...
Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be ...
Moderna, Inc. (MRNA) Withdraws Application for COVID-flu Combination Vaccine
Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...
TMCnet6h
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) ...
Morningstar2mon
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...